Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Phase 2 Unknown 60 enrolled Sichuan Cancer Hospital and Research Institute

RandomizedParallel-groupDouble-blindTreatment

Summary

The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.

Timeline

Start: 2017-08-27
Primary completion: 2020-08
Completion: 2021-02

Publications

Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	500 mg	Oral

Indications

No indication recorded.